NCT02108418View on ClinicalTrials.gov

Study to Evaluate the PK, Relative Bioavailability and Safety of TG-2349 With Single Oral Dose Under Fed Condition in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

April 30, 2014

Primary Completion Date

June 30, 2014

Study Completion Date

July 31, 2014

Conditions
Healthy
Interventions
DRUG

TG-2349 as the original formulation

single oral dose under fed condition

DRUG

TG-2349 as a new capsule formulation

single oral dose under fed condition

Trial Locations (1)

90630

WCCT, Cypress

All Listed Sponsors
lead

TaiGen Biotechnology Co., Ltd.

INDUSTRY

NCT02108418 - Study to Evaluate the PK, Relative Bioavailability and Safety of TG-2349 With Single Oral Dose Under Fed Condition in Healthy Volunteers | Biotech Hunter | Biotech Hunter